Daichi-Sankyo

The deal marks the first pharma alliance for Evotec since it acquired Kinaxo in mid-April in a deal worth up to $23 million.

Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.

The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.